MedX Health Corp. Announces Executive Changes

MISSISSAUGA, ONTARIO--(Marketwired - Nov. 29, 2013) - The Board of Directors of MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX) is pleased to announce the following Senior Executive changes.

Gary Van Nest will retire as Chairman, and remain as a Director of the Company.

Steven Guillen, MBA, the current Chief Executive Officer (CEO), and a Director, will become Chairman of the Board.

Robert von der Porten, MBA, of Toronto, a well-known and respected Senior Operating Executive, also well experienced in finance, corporate development, strategy, and implementation over a broad range of industries, will become, President & Chief Executive Officer (CEO), and a Director of the Corporation.

Louie Canitano, B.Sc, currently President and Chief Operating Officer (COO), will continue the role of Chief Operating Officer (COO) of the Corporation.

Jim Cooke, CPA, CA, will become Chief Financial Officer (CFO) of the Corporation. Jim is an experienced financial executive and has worked with large and small companies in a variety of industries, in all phases of the corporate growth cycle.

These appointments reflect the dimensions of the business opportunity currently facing MedX as it launches into the skin cancer screening marketplace on a global basis and the need for experienced operational talent at the executive level in order to maximize the business opportunities at hand.

"MedX has a world class technology to assist in the screening and detection of skin cancers offering significant benefits to communities around the world in which we plan to introduce it to: I am very excited to have the opportunity to be part of this" said Mr. von der Porten.

These appointments, which have been approved by the Board of Directors of MedX, are subject to all relevant regulatory and other consents and approvals.

About MedX

MedX, headquartered in Mississauga, Ontario (Toronto), and is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technologies for use in numerous medical settings, including rehab/chiropractic, dental, wound care, and veterinary medicine, providing patients with drug free and non-invasive treatment of tissue damage and pain. MedX laser and light products are FDA approved, Health Canada cleared, and CE Mark approved for use in North America as well as the European Union. MedX Health acquired the worldwide assets of SIMSYS™ and MoleMate™ in June, 2011. For a complete profile of MedX and its products visit www.medxhealth.com.

About SIMSYS™ and MoleMate™ Skin Cancer Imaging

SIMSYS™ and MoleMate™ received approval from Health Canada, and are available for all Canadian physicians and dermatologist. SIMSYS™ and MoleMate™ is also FDA approved for use in the USA and is currently under review for CE approval for use in Europe, the UK, and Australia. For more information log onto: www.simsys-molemate.com and click on 'See More', and see approximately 2mm below the surface of suspicious moles and lesions with additional information and images related to every mole and lesions associated with all types of melanomas and non-melanomas. SIMSYS™ and MoleMate™ is an optical biopsy that uses patented technology that features a hand-held scanner device designed for clinical office use that utilizes light to view beneath suspicious moles or lesions in a pain free, non-invasive manner, creating images in real-time for physicians and dermatologist to evaluate all types of moles or lesions within seconds, providing images that can reveal if a mole or lesion is benign, or something more serious, often eliminating the need for skin biopsies, resulting in less pain, scarring, and expense. Physicians and dermatologist interested in learning more should contact MedX Health Corp. or log onto www.simsys-molemate.com.

This press release may contain forward-looking statements, including statements regarding the business and anticipated financial performance of MedX Health Corp., which involve risks and uncertainties. These risks and uncertainties may cause MedX's actual results to differ materially from those contemplated by the forward-looking statements. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.